Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 May 2004Website:
http://www.acadia.comNext earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 14 Nov 2024 23:27:11 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
ACAD Latest News
ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, Acadia.com under the investors section and will be archived.
Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. “We are excited to welcome Catherine Owen Adams as the new CEO of Acadia,” said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. “Catherine is a proven global leader with a distinguished record of accomplishment of driving growth and innovation in the pharmaceutical indus.
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.01 per share a year ago.
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
What type of business is ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals Inc. is an American biopharmaceutical company headquartered in San Diego, California, focused on the development and commercialization of innovative drugs for patients with central nervous system disorders. It was founded in 1993 as Receptor Technologies, Inc. The company commercializes the drug NUPLAZID (Pimavanserin), which was approved by the U.S. Food and Drug Administration (FDA) in April 2016 for the treatment of psychosis in Parkinson's disease (PD psychosis) and is the first and only drug approved in the U.S. for this condition. Additionally, the company continues to study the use of the drug for the treatment of other neurological and psychiatric disorders.
What sector is ACADIA Pharmaceuticals in?
ACADIA Pharmaceuticals is in the Healthcare sector
What industry is ACADIA Pharmaceuticals in?
ACADIA Pharmaceuticals is in the Biotechnology industry
What country is ACADIA Pharmaceuticals from?
ACADIA Pharmaceuticals is headquartered in United States
When did ACADIA Pharmaceuticals go public?
ACADIA Pharmaceuticals initial public offering (IPO) was on 27 May 2004
What is ACADIA Pharmaceuticals website?
https://www.acadia.com
Is ACADIA Pharmaceuticals in the S&P 500?
No, ACADIA Pharmaceuticals is not included in the S&P 500 index
Is ACADIA Pharmaceuticals in the NASDAQ 100?
No, ACADIA Pharmaceuticals is not included in the NASDAQ 100 index
Is ACADIA Pharmaceuticals in the Dow Jones?
No, ACADIA Pharmaceuticals is not included in the Dow Jones index
When was ACADIA Pharmaceuticals the previous earnings report?
No data
When does ACADIA Pharmaceuticals earnings report?
The next expected earnings date for ACADIA Pharmaceuticals is 27 February 2025